Evidence map›Paper›PMID 40167901›Full record

ArticleMolecular biology reports2025

Fisetin mitigates cisplatin-induced peripheral neuropathy: a behavioral and immunohistochemical study.

Cansel Adıgüzel, Caner Yildirim, Sena Çevik, Şenay Görücü Yilmaz, Ramazan Bal

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cansel AdıgüzelDepartment of Physiology, Faculty of Medicine, Gaziantep University, Gaziantep, 27310, Turkey.ORCID https://orcid.org/0009-0004-1437-1969
Caner YildirimDepartment of Physiology, Faculty of Medicine, Gaziantep University, Gaziantep, 27310, Turkey. caneryildirim27@gmail.com.ORCID https://orcid.org/0000-0003-0091-9925
Sena ÇevikDepartment of Physiology, Faculty of Medicine, Gaziantep University, Gaziantep, 27310, Turkey.ORCID https://orcid.org/0000-0003-4679-2800
Şenay Görücü YilmazFaculty of Health Sciences, Department of Nutrition and Dietetics, Gaziantep University, Gaziantep, Turkey.ORCID http://orcid.org/0000-0003-0523-7819
Ramazan BalDepartment of Physiology, Faculty of Medicine, Gaziantep University, Gaziantep, 27310, Turkey.ORCID https://orcid.org/0000-0003-3829-8669

Funding

Research Project Management Unit at the University of Gaziantep TF.YLT.24.02
6 · The paper itself

Abstract

backgroundCisplatin (CIS), a commonly used chemotherapeutic drug, often causes peripheral neuropathy, considerably affecting patients' quality of life. The present study investigated the neuroprotective effects of fisetin, a natural flavonoid with antioxidant and anti-inflammatory features, in a rat model of cisplatin-induced peripheral neuropathy. METHODS AND

resultsMale Wistar rats were divided into six groups: sham, neuropathy (CIS, 3 mg/kg, 5 weeks), fisetin treatment (CIS + 10 mg/kg and CIS + 20 mg/kg), and drugs control groups (10 mg/kg and 20 mg/kg fisetin alone). Behavioural experiments were conducted to evaluate motor coordination and sensory function, electrophysiologically measured nerve conduction velocity (NCV). Gene expression studies were conducted for NF-kB and GPX4 to investigate oxidative stress and inflammation. Finally, confocal microscopy studies were used to evaluate the structure of the sciatic nerve. Cisplatin induced motor impairments, sensory dysfunction, mechanical allodynia, diminished nerve conduction velocity, myelin deterioration (decreased MBP), and increased neuroinflammation (elevated GFAP and NF-kB, decreased GPX4). Fisetin, specifically at a dose of 10 mg/kg, markedly enhanced motor coordination, sensory thresholds, NCV, maintained myelin integrity, reduced glial activation, and restored oxidative and inflammatory balance by elevating GPX4 levels and decreasing NF-kB expression.

conclusionsThese results highlight fisetin's potential as a therapeutic agent for cisplatin-induced neuropathy, emphasising its role in restoring molecular, structural, and functional integrity within the peripheral nervous system.

Indexed as

CisplatinFlavonoidsFlavonolsPeripheral Nervous System DiseasesAnimalsAntineoplastic AgentsAntioxidantsBehavior, AnimalDisease Models, AnimalImmunohistochemistryMaleNeural ConductionNeuroprotective AgentsNF-kappa BOxidative StressRatsAntineoplastic AgentsAntioxidantsCisplatinfisetinFlavonoidsFlavonolsNeuroprotective AgentsNF-kappa BCisplatinFisetinMyelin basic proteinNerve conduction velocityNeuropathyNociceptive behaviour experiment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.